- Company Establishes U.S. subsidiary in Philadelphia Area -
PHILADELPHIA, Feb. 13 /PRNewswire/ -- Cellvizio Inc., a leader in in vivo cellular imaging, announced today the appointment of Chris Tihansky as its President. Cellvizio Inc. is the U.S. subsidiary of Paris-based Mauna Kea Technologies and develops and markets Cellvizio(R), a fundamentally new endoscopic imaging approach which improves patient care by eliminating the need for unnecessary biopsies and enhances the diagnosis of a broad range of diseases via in vivo cellular imaging.
The appointment coincides with the company establishing its U.S. operations base in the Philadelphia area.
"Cellvizio is increasing its commercialization efforts in the U.S., and Chris is a great fit for leading this," said Sacha Loiseau, Ph.D., founder, president and chief executive officer of Mauna Kea. "He has a unique combination of expertise in the medical technology field, including general management, business development, sales, and product development."
"Cellvizio is an excellent example of a company that has successfully taken a cutting-edge technology from bench top to bedside," explained Chris. "I am very pleased to be leading our team in the U.S. It is our intention to make Cellvizio a standard of care so that as many patients as possible have access to the advantages this technology offers."
"The Philadelphia area is a perfect location for us to rapidly build our business," Chris stated. "It offers ready access to our customer base and a strong talent pool. Additionally, it is increasingly evident that Southeastern Pennsylvania offers a well-developed support infrastructure for emerging med- tech companies."
Chris has 20 years of experience in the emerging medical technology and
healthcare financials services industri
|SOURCE Cellvizio Inc.|
Copyright©2008 PR Newswire.
All rights reserved